Evidence map›Paper›PMID 36572559›Full record

ArticleMolecules and cells2022

RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.

Masamitsu Mikami, Tatsuya Masuda, Takuya Kanatani, Mina Noura, Katsutsugu Umeda, Hidefumi Hiramatsu, Hirohito Kubota, Tomoo Daifu, Atsushi Iwai, Etsuko Yamamoto Hattori and 16 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules and cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 1 country.

Masamitsu MikamiDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0002-6565-9872
Tatsuya MasudaDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Takuya KanataniDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Mina NouraDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Katsutsugu UmedaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0002-6844-2011
Hidefumi HiramatsuDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0003-3136-5670
Hirohito KubotaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0002-6935-5120
Tomoo DaifuDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0002-9276-7019
Atsushi IwaiDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Etsuko Yamamoto HattoriDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0002-2975-774X
Kana FuruichiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Saho TakasakiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Sunao TanakaDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Yasuzumi MatsuiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
Hidemasa MatsuoDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0002-7578-006X
Masahiro HirataDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto 606-8507, Japan.
Tatsuki R KataokaDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto 606-8507, Japan.ORCID https://orcid.org/0000-0003-3095-8976
Tatsutoshi NakahataDrug Discovery Technology Development Office, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.ORCID https://orcid.org/0000-0003-0427-8440
Yasumichi KuwaharaDepartment of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.ORCID https://orcid.org/0000-0002-0139-8503
Tomoko IeharaDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Hajime HosoiDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Yoichi ImaiDepartment of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.ORCID https://orcid.org/0000-0002-2938-6133
Junko TakitaDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0002-2452-6520
Hiroshi SugiyamaDepartment of Chemistry, Graduate School of Science, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0001-8923-5946
Souichi AdachiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0002-8473-0187
Yasuhiko KamikuboDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.ORCID https://orcid.org/0000-0003-2761-8508
Kyoto University · JPKyoto Prefectural University of Medicine · JPKyoto University Hospital · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant rhabdoid tumor (MRT) is a highly aggressive pediatric malignancy with no effective therapy. Therefore, it is necessary to identify a target for the development of novel molecule-targeting therapeutic agents. In this study, we report the importance of the runt-related transcription factor 1 (

Indexed as

Core Binding Factor Alpha 2 SubunitRhabdoid TumorSurvivinApoptosisBase SequenceCell Line, TumorHumansBIRC5 protein, humanCore Binding Factor Alpha 2 SubunitRUNX1 protein, humanSurvivinmalignant rhabdoid tumorpolyamideRUNX1survivin

Identifiers

PMID36572559
PMCPMC9794559
OpenAlexW4312217873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.